Tearsheet

Rafael (RFL)


Market Price (12/25/2025): $1.17 | Market Cap: $59.9 Mil
Sector: Real Estate | Industry: Real Estate Services

Rafael (RFL)


Market Price (12/25/2025): $1.17
Market Cap: $59.9 Mil
Sector: Real Estate
Industry: Real Estate Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.


0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -74%
Weak multi-year price returns
2Y Excs Rtn is -82%, 3Y Excs Rtn is -113%
Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -32 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3149%
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 48%
  Expensive valuation multiples
P/SPrice/Sales ratio is 59x
2 Megatrend and thematic drivers
Megatrends include Advanced Aviation & Space, Artificial Intelligence, and Cybersecurity. Themes include Drone Technology, Show more.
  Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 230%
3   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -2205%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2206%
4   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -56%
5   Key risks
RFL key risks include [1] its critical dependence on the clinical success of its single lead drug candidate, Show more.
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -74%
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 48%
2 Megatrend and thematic drivers
Megatrends include Advanced Aviation & Space, Artificial Intelligence, and Cybersecurity. Themes include Drone Technology, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -82%, 3Y Excs Rtn is -113%
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -32 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3149%
5 Expensive valuation multiples
P/SPrice/Sales ratio is 59x
6 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 230%
7 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -2205%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2206%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -56%
9 Key risks
RFL key risks include [1] its critical dependence on the clinical success of its single lead drug candidate, Show more.

Valuation, Metrics & Events

RFL Stock


Why The Stock Moved


Qualitative Assessment

AI Analysis | Feedback

Here are the key points explaining the -19.7% stock movement for Rafael Holdings, Inc. (RFL) for the approximate time period from August 31, 2025, to December 25, 2025: 1. The stock exhibited a strong negative trend and significant recent declines. Rafael Holdings, Inc. shares experienced a fall of -24.52% in the ten days leading up to December 23, 2025, and a monthly decrease of -5.24%. This indicates a consistent downward trajectory for the stock during the specified period.

2. The stock reached an all-time low during this period. On November 25, 2025, RFL's stock price hit an all-time low of $1.17. As of December 23, 2025, the price remained near its 52-week low of $1.16. This suggests a significant loss of investor confidence and a prolonged struggle for the company.

Show more

Stock Movement Drivers

Fundamental Drivers

The -16.3% change in RFL stock from 9/24/2025 to 12/24/2025 was primarily driven by a -99.9% change in the company's Shares Outstanding (Mil).
924202512242025Change
Stock Price ($)1.411.18-16.31%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)0.731.0340.57%
P/S Multiple49.3158.7019.03%
Shares Outstanding (Mil)25.6051.18-99.93%
Cumulative Contribution-99.89%

LTM = Last Twelve Months as of date shown

Market Drivers

9/24/2025 to 12/24/2025
ReturnCorrelation
RFL-16.3% 
Market (SPY)4.4%5.2%
Sector (XLRE)-2.7%-8.6%

Fundamental Drivers

The -28.5% change in RFL stock from 6/25/2025 to 12/24/2025 was primarily driven by a -99.9% change in the company's Shares Outstanding (Mil).
625202512242025Change
Stock Price ($)1.651.18-28.48%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)0.731.0340.57%
P/S Multiple57.7158.701.71%
Shares Outstanding (Mil)25.6051.18-99.93%
Cumulative Contribution-99.91%

LTM = Last Twelve Months as of date shown

Market Drivers

6/25/2025 to 12/24/2025
ReturnCorrelation
RFL-28.5% 
Market (SPY)14.0%12.7%
Sector (XLRE)-1.2%13.0%

Fundamental Drivers

The -33.5% change in RFL stock from 12/24/2024 to 12/24/2025 was primarily driven by a -109.7% change in the company's Shares Outstanding (Mil).
1224202412242025Change
Stock Price ($)1.771.18-33.50%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)0.701.0347.63%
P/S Multiple62.1458.70-5.54%
Shares Outstanding (Mil)24.4151.18-109.70%
Cumulative Contribution-113.53%

LTM = Last Twelve Months as of date shown

Market Drivers

12/24/2024 to 12/24/2025
ReturnCorrelation
RFL-33.5% 
Market (SPY)15.8%14.7%
Sector (XLRE)1.4%13.7%

Fundamental Drivers

The -32.4% change in RFL stock from 12/25/2022 to 12/24/2025 was primarily driven by a -119.2% change in the company's Shares Outstanding (Mil).
1225202212242025Change
Stock Price ($)1.751.18-32.38%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)0.291.03256.06%
P/S Multiple140.9658.70-58.36%
Shares Outstanding (Mil)23.3551.18-119.25%
Cumulative Contribution-128.53%

LTM = Last Twelve Months as of date shown

Market Drivers

12/25/2023 to 12/24/2025
ReturnCorrelation
RFL-34.6% 
Market (SPY)48.9%12.6%
Sector (XLRE)7.8%10.6%

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
RFL Return31%-78%-63%-2%-10%-28%-93%
Peers Return-10%23%25%-4%12%34%99%
S&P 500 Return16%27%-19%24%23%18%115%

Monthly Win Rates [3]
RFL Win Rate58%42%25%50%25%17% 
Peers Win Rate47%58%57%45%62%65% 
S&P 500 Win Rate58%75%42%67%75%73% 

Max Drawdowns [4]
RFL Max Drawdown-42%-79%-68%-22%-26%-28% 
Peers Max Drawdown-32%-7%-2%-21%-5%-8% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: RTX, LMT, NOC, GD, LHX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)

How Low Can It Go

Unique KeyEventRFLS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-97.7%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven4285.5%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-53.9%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven117.1%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven259 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-46.2%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven86.0%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven454 days120 days

Compare to OPEN, GBR, GYRO, LHAI, CBRE

In The Past

Rafael's stock fell -97.7% during the 2022 Inflation Shock from a high on 7/12/2021. A -97.7% loss requires a 4285.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Rafael (RFL)

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

AI Analysis | Feedback

Here are 1-3 brief analogies to describe Rafael:

  • An Israeli Lockheed Martin.
  • Like Raytheon (now RTX), but an Israeli firm specializing in advanced defense systems.
  • The Northrop Grumman of Israel, developing cutting-edge military technology.

AI Analysis | Feedback

  • Iron Dome: A mobile all-weather air defense system primarily designed to intercept and destroy short-range rockets and artillery shells.
  • Spike Missile Family: A series of electro-optical, multi-purpose, multi-platform precision-guided missiles used for anti-tank and other precision strike missions.
  • David's Sling: A joint Israel-US military system designed to intercept medium- to long-range rockets and cruise missiles.
  • Trophy Active Protection System (APS): A military system designed to protect armored vehicles from anti-tank guided missiles, rockets, and other threats.
  • Litening Targeting Pod: An advanced airborne targeting and navigation pod system that provides pilots with real-time, all-weather, day/night targeting capabilities.
  • Spyder Air Defense System: A family of quick-reaction, low-level surface-to-air missile systems for defending against aircraft and various munitions.

AI Analysis | Feedback

Rafael Advanced Defense Systems Ltd. primarily sells its advanced defense systems to governments and other defense companies, operating in a Business-to-Government (B2G) and Business-to-Business (B2B) model. It does not sell directly to individuals.

Major Customers:

  • Israeli Ministry of Defense (IMOD): As Israel's leading defense technology company, the Israel Defense Forces (IDF) and the Israeli Ministry of Defense are Rafael's primary and largest domestic customers. This is a government entity and not a public company.
  • RTX Corporation (symbol: RTX): Through its Raytheon division, RTX is a significant international partner and customer of Rafael. They collaborate on the co-production and integration of key Rafael systems, such as the Iron Dome and David's Sling air defense systems, for the U.S. military and other global markets.
  • Various Foreign Governments: Rafael is a major global exporter, with a substantial portion of its sales going to numerous governments and their respective defense ministries worldwide. These customers span various regions, including Europe, Asia, and North America. These are government entities and not public companies.

AI Analysis | Feedback

null

AI Analysis | Feedback

Yoav Turgeman, Chief Executive Officer

Yoav Turgeman was appointed CEO of Rafael Advanced Defense Systems Ltd. in December 2023, succeeding Yoav Har-Even. Prior to this role, he served as the CEO of Elta Systems, a subsidiary of Israel Aerospace Industries (IAI), a position he held since 2018. Turgeman joined IAI in 2006 after a 25-year career in the Israeli Navy, where he retired as a colonel and headed its combat systems department. At IAI, he held various positions, including leading the Arrow air defense system program and managing the company's anti-aircraft plant. He is credited with strengthening Elta's cyber, autonomous combat vehicle, and patrol vehicle businesses. He holds bachelor's and master's degrees with honors in electrical engineering from Tel Aviv University, along with additional degrees from the University of Haifa and Bar Ilan University.

Moshe Lipel, Executive Vice President of Finance and Control (CFO)

Brigadier General (Ret.) Moshe Lipel was appointed Executive Vice President of Finance and Control (CFO) of Rafael Advanced Defense Systems Ltd. in November 2020. He replaced David Vaish, who retired after 15 years as the company's CFO. For 13 years prior to joining Rafael, Lipel served as the CFO of Elta Systems Ltd., an IAI subsidiary. His background also includes various positions within Israel's defense establishment, such as financial advisor to the Chief of Staff of the IDF and head of the Defense Ministry's budget department. Mr. Lipel holds a Bachelor of Business Administration degree from Bar Ilan University, specializing in Finance.

Pini Yungman, Executive Vice President; General Manager - Air & Missile Defense Division

Pini Yungman serves as an Executive Vice President and the General Manager of the Air & Missile Defense Division at Rafael Advanced Defense Systems Ltd. He was among the serving vice presidents at Rafael considered for the CEO position.

Judith Hocherman-Frommer, Executive Vice President - Research and Development

Judith Hocherman-Frommer is the Executive Vice President for Research and Development at Rafael Advanced Defense Systems Ltd., a position she has held since 2023.

Yuval Miller, Executive Vice President

Yuval Miller holds the title of Executive Vice President at Rafael Advanced Defense Systems Ltd. He previously served as the head of the air and intelligence division and was considered as a candidate for the CEO position.

AI Analysis | Feedback

The key risks to Rafael Holdings Inc. (symbol: RFL), a clinical-stage pharmaceutical company with interests in healthcare, infusion technology, and real estate, are primarily associated with the inherent uncertainties of drug development and its financial stability.

  1. Clinical Trial and Drug Development Risk: Rafael Holdings' business success is highly dependent on the successful development and commercialization of its lead drug candidate, Trappsol Cyclo, which is in Phase 3 clinical trials for Niemann-Pick Disease Type C1 (NPC1). The pharmaceutical development process is fraught with uncertainty, and the failure of a drug candidate at any stage of clinical trials can significantly devalue the company. The company previously experienced a substantial setback when its former lead oncology drug candidate, Devimistat, failed in pivotal trials in 2021, leading to a significant decline in the pharmaceutical segment's value and a strategic pivot.
  2. Financial Viability and Need for Additional Financing: Rafael Holdings Inc. has a history of generating limited revenues and incurring net operating losses. As a clinical-stage pharmaceutical company, it requires substantial funding for its research and development programs, particularly for advancing drug candidates through costly clinical trials. This reliance on additional financing poses a risk to the company's continued operations and growth.
  3. Regulatory and Market Competition Risk: As with any pharmaceutical company, Rafael Holdings Inc. faces risks associated with obtaining regulatory approvals for its drug candidates. The highly competitive nature of the pharmaceutical industry also means that the emergence of new or more effective treatments from competitors could impact the potential market share and profitability of its products, even if successfully developed and approved.

AI Analysis | Feedback

The accelerating pace of innovation and successful commercialization of novel oncology therapies by well-capitalized pharmaceutical and biotechnology companies represents a clear emerging threat. These new therapies continuously redefine standards of care and capture market share in therapeutic areas Rafael Pharmaceuticals aims to target, making it increasingly difficult for its lead candidate, devimistat, to establish a viable market presence, particularly given its prior clinical setbacks in pancreatic cancer.

AI Analysis | Feedback

Rafael Advanced Defense Systems Ltd. (RFL) operates in several key defense technology markets. The addressable market sizes for its main products and services vary by product category and region, primarily spanning global and regional defense sectors.

Main Products and Addressable Markets:

  • Iron Dome (Air Defense System): The global market for advanced missile defense systems, which includes Iron Dome, is expected to see sales exceeding $10 billion in the next five years. The broader global air defense systems market size was valued at USD 87.63 billion in 2024 and is projected to grow to USD 154.81 billion by 2032, at a Compound Annual Growth Rate (CAGR) of 7.11% from 2025 to 2032.
  • Spike Missiles (Anti-Tank Guided Missiles): Rafael has sold over 30,000 Spike missiles to 32 customers, with the Spike family being used in 45 nations globally. Recent significant deals include Germany's procurement of Spike anti-tank missiles valued at approximately 2 billion euros. The global missile market, encompassing Spike missiles, was estimated at USD 55.70 billion in 2023 and is projected to reach USD 93.56 billion by 2030, growing at a CAGR of 7.4% from 2024 to 2030. North America dominated this market with a revenue share over 39.37% in 2023, while Asia-Pacific is noted as the fastest-growing market.
  • David's Sling (Air Defense System): David's Sling operates within the global surface-to-air missile (SAM) market, which was estimated at approximately $12 billion in 2023 and can be valued in the "tens of billions of dollars" for 2025. This market is projected to increase from USD 6.21 billion in 2025 to approximately USD 10.78 billion by 2034, expanding at a CAGR of 6.32% from 2025 to 2034. Notable sales include a €316 million (approximately $354 million) contract with Finland.
  • Trophy Active Protection System (APS): The global active protection systems market size was valued at USD 3.76 billion in 2024 and is projected to grow to nearly USD 6.70 billion by 2032, at a CAGR of 7.5% from 2025. Other estimates place the market at USD 4.42 billion in 2024, expanding to USD 5.91 billion by 2030 at a 5.98% CAGR, and at USD 5.64 billion in 2025, reaching around USD 8.76 billion by 2034 at a 5.01% CAGR. North America is a dominant region, holding 34.28% of the market in 2024 and surpassing USD 1.88 billion in 2024, projected to grow at a CAGR of 5.16% during the forecast period. Europe also holds a significant share, with 38.78% of revenue in 2024, and is expected to grow significantly.
  • Litening Targeting Pod (Targeting Pods): The global targeting pods market size was valued at USD 5.36 billion in 2024 and is expected to grow at a CAGR of 8.2% from 2025 to 2030. Another report estimates the market size at USD 5.65 billion in 2025, projected to reach USD 8.24 billion by 2030 at a 7.84% CAGR. North America dominated this market, accounting for 32.8% of global revenue in 2024 and 38.25% in 2024. Asia-Pacific is projected to exhibit the highest regional CAGR at 8.97% through 2030. Rafael has sold over 2,000 Litening units to 28 air forces worldwide.
  • Python Missiles (Air-to-Air Missiles): Python missiles are part of the broader global missile market, which was estimated at USD 55.70 billion in 2023 and is projected to reach USD 93.56 billion by 2030. The air segment, which includes air-to-air missiles, accounted for the largest revenue share of 42.3% in the missile market in 2023.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Rafael Advanced Defense Systems Ltd. over the next 2-3 years:

  1. Growing Order Backlog: Rafael reported an unprecedented order backlog of $17.76 billion in 2024, a 24% increase from the previous year, with nearly half of these orders stemming from export contracts. This substantial backlog represents approximately 3.6 years of sales, providing a strong foundation for future revenue generation. Analysts also estimate Rafael's order backlog to be around $18 billion, equivalent to more than three years of revenue, suggesting consistent future income.
  2. Increased Global Defense Budgets and Demand: The company's operational performance is significantly benefiting from governments' increased defense budgets and a strengthening demand across the broader defense industry. Ongoing global conflicts are contributing to a surge in demand for Rafael's products and services, acting as a tailwind for the company.
  3. International Expansion and Strategic Partnerships: Approximately half of Rafael's sales in 2024 were directed to international customers. The company's strategy emphasizes strategic international partnerships and localization efforts to ensure customer sovereignty. Rafael's key international markets include the US, Europe, the Asia-Pacific region, the Middle East, Latin America, and Africa, with customers in 20 NATO countries. Notable expansions include a new production facility in Arkansas, USA, for Tamir interceptor manufacturing and the integration of its Trophy system on Germany's Leopard tank.
  4. Development and Launch of New, Advanced Defense Systems: Rafael consistently invests approximately 8% of its annual revenue into research and development. This investment fuels the creation of next-generation technologies and future systems. The company has showcased advancements such as the successful testing of the IRON BEAM High Energy Laser Weapon System, which complements the IRON DOME system, and continues to innovate in areas like advanced aerodynamics, autonomous systems, artificial intelligence, and cyber warfare.
  5. Sustained Demand for Existing Combat-Proven Technologies: Rafael's established and combat-proven defense systems, including Iron Dome, David's Sling, and Trophy, continue to experience strong global demand due to their critical protection capabilities. For instance, the company secured a contract in 2024 to supply the David's Sling air defense system to Finland, underscoring the ongoing need for its core products.

AI Analysis | Feedback

Rafael Advanced Defense Systems Ltd. is a government-owned company in Israel and is not publicly traded under the symbol RFL. Therefore, information related to share repurchases and share issuances in the context of a public company's capital allocation decisions is not applicable.

Inbound Investments

  • Rafael Advanced Defense Systems received a grant of $469K from the European Union in October 2023.
  • The company secured an undisclosed amount in funding in April 2021.

Outbound Investments

  • In 2023, Rafael acquired the remaining part of Aeronautics, making it fully owned, for approximately ILS 500 million.
  • Rafael, in a joint venture with Raytheon (R2S), inaugurated a new production facility in Arkansas, USA, for manufacturing Tamir interceptors, representing an investment of tens of millions of dollars.
  • Rafael continuously invests in investee companies, partially implementing its annual budget for acquisitions of company shares between 2017 and 2021.

Capital Expenditures

  • Rafael's capital expenditures are expected to rise gradually to more than ILS 1 billion in 2024 and slightly higher in 2025.
  • The company consistently allocates approximately 8% of its annual revenue to research and development.
  • Capital expenditures include expanding its development footprint by opening a new branch in Hadera, complementing existing R&D centers in northern Israel, Be'er Sheva, Jerusalem, and Tel Aviv.

Better Bets than Rafael (RFL)

Latest Trefis Analyses

Title
0ARTICLES

Trade Ideas

Select ideas related to RFL. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
MPW_10312025_Short_Squeeze10312025MPWMedical Properties TrustSpecialShort Squeeze PotentialShort Squeeze Potential
Has potential for a short squeeze. High short interest, rising short interest and high debt.
-0.7%-0.7%-5.8%

Recent Active Movers

More From Trefis

Peer Comparisons for Rafael

Peers to compare with:

Financials

RFLRTXLMTNOCGDLHXMedian
NameRafael RTX Lockheed.Northrop.General .L3Harris. 
Mkt Price1.18186.38485.75582.35345.39298.14321.76
Mkt Cap0.1250.3112.683.393.055.888.2
Rev LTM185,98873,34940,92851,50921,37346,218
Op Inc LTM-328,8155,9974,0985,3272,3664,712
FCF LTM-234,7264,5931,8344,8122,1643,378
FCF 3Y Avg-145,5475,6342,1373,3951,8282,766
CFO LTM-237,9636,3613,4385,7192,5074,578
CFO 3Y Avg-148,6917,3863,7914,3502,2084,071

Growth & Margins

RFLRTXLMTNOCGDLHXMedian
NameRafael RTX Lockheed.Northrop.General .L3Harris. 
Rev Chg LTM47.6%8.8%2.9%-0.1%11.9%2.9%5.9%
Rev Chg 3Y Avg65.0%9.4%4.3%5.2%9.9%8.4%8.9%
Rev Chg Q87.5%11.9%8.8%4.3%10.6%2.4%9.7%
QoQ Delta Rev Chg LTM12.2%2.9%2.1%1.1%2.5%0.6%2.3%
Op Mgn LTM-3,149.3%10.3%8.2%10.0%10.3%11.1%10.1%
Op Mgn 3Y Avg-7,512.8%7.7%11.0%9.0%10.2%10.4%9.6%
QoQ Delta Op Mgn LTM-302.1%0.3%0.0%0.2%0.0%0.2%0.1%
CFO/Rev LTM-2,204.9%9.3%8.7%8.4%11.1%11.7%9.0%
CFO/Rev 3Y Avg-2,407.7%11.3%10.5%9.4%9.3%11.0%9.9%
FCF/Rev LTM-2,205.6%5.5%6.3%4.5%9.3%10.1%5.9%
FCF/Rev 3Y Avg-2,416.7%7.2%8.0%5.3%7.3%9.2%7.2%

Valuation

RFLRTXLMTNOCGDLHXMedian
NameRafael RTX Lockheed.Northrop.General .L3Harris. 
Mkt Cap0.1250.3112.683.393.055.888.2
P/S58.72.91.52.01.82.62.3
P/EBIT-1.824.018.815.117.022.017.9
P/E-1.938.026.820.722.132.924.4
P/CFO-2.731.417.724.216.322.220.0
Total Yield-51.9%4.0%5.8%5.6%6.2%4.6%5.1%
Dividend Yield0.0%1.4%2.1%0.8%1.7%1.6%1.5%
FCF Yield 3Y Avg-24.8%3.7%4.8%2.8%4.4%4.2%4.0%
D/E0.00.20.20.20.10.20.2
Net D/E-0.70.10.20.20.10.20.2

Returns

RFLRTXLMTNOCGDLHXMedian
NameRafael RTX Lockheed.Northrop.General .L3Harris. 
1M Rtn-4.8%7.6%8.5%3.4%2.1%8.3%5.5%
3M Rtn-16.3%15.9%0.7%-0.3%7.2%5.4%3.0%
6M Rtn-28.5%32.9%7.6%20.6%22.0%21.3%20.9%
12M Rtn-33.5%62.5%2.4%25.8%32.6%42.4%29.2%
3Y Rtn-32.4%100.8%9.1%14.5%48.5%54.1%31.5%
1M Excs Rtn-8.2%4.2%5.1%0.0%-1.2%4.9%2.1%
3M Excs Rtn-18.2%11.6%-3.9%-5.1%2.0%-1.4%-2.7%
6M Excs Rtn-42.6%18.9%-5.2%6.0%6.8%9.0%6.4%
12M Excs Rtn-55.5%46.1%-14.6%9.3%16.8%25.4%13.1%
3Y Excs Rtn-113.2%22.9%-72.2%-66.6%-30.9%-27.0%-48.8%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Infusion Technology00   
Real Estate00015
Healthcare000  
Pharmaceuticals    0
Total10015


Operating Income by Segment
$ Mil20252024202320222021
Real Estate0001-6
Infusion Technology-10   
Healthcare-102-15-61-29 
Pharmaceuticals    -3
Total-103-15-60-28-8


Price Behavior

Price Behavior
Market Price$1.18 
Market Cap ($ Bil)0.0 
First Trading Date03/27/2018 
Distance from 52W High-58.6% 
   50 Days200 Days
DMA Price$1.30$1.57
DMA Trenddowndown
Distance from DMA-8.9%-24.6%
 3M1YR
Volatility56.3%84.4%
Downside Capture64.92184.06
Upside Capture-31.54117.08
Correlation (SPY)5.5%14.3%
RFL Betas & Captures as of 11/30/2025

 1M2M3M6M1Y3Y
Beta0.170.300.671.800.690.56
Up Beta0.430.640.950.600.070.12
Down Beta-1.29-0.67-0.16-1.210.360.39
Up Capture-76%-2%12%347%132%44%
Bmk +ve Days13263974142427
Stock +ve Days5121948101316
Down Capture98%106%150%305%138%103%
Bmk -ve Days7162452107323
Stock -ve Days9213365128354

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
 Comparison of RFL With Other Asset Classes (Last 1Y)
 RFLSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-33.5%4.4%19.2%71.9%8.9%6.0%-10.4%
Annualized Volatility84.5%16.9%19.5%19.3%15.3%17.1%35.0%
Sharpe Ratio-0.110.090.782.690.360.18-0.12
Correlation With Other Assets 14.3%14.7%5.5%-3.3%14.7%19.2%

ETFs used for asset classes: Sector ETF = XLRE, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
 Comparison of RFL With Other Asset Classes (Last 5Y)
 RFLSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-44.0%5.5%14.9%18.7%11.7%4.8%32.6%
Annualized Volatility74.0%19.1%17.1%15.5%18.7%18.9%48.7%
Sharpe Ratio-0.370.200.700.970.510.170.59
Correlation With Other Assets 15.4%20.3%2.9%2.6%16.7%15.2%

ETFs used for asset classes: Sector ETF = XLRE, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
 Comparison of RFL With Other Asset Classes (Last 10Y)
 RFLSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-16.7%6.2%14.7%14.9%6.9%5.2%69.2%
Annualized Volatility74.4%20.6%18.0%14.8%17.6%20.8%55.8%
Sharpe Ratio0.140.270.700.830.310.220.90
Correlation With Other Assets 25.0%29.3%1.6%9.9%26.7%13.0%

ETFs used for asset classes: Sector ETF = XLRE, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date12152025
Short Interest: Shares Quantity40,257
Short Interest: % Change Since 11302025-44.7%
Average Daily Volume210,772
Days-to-Cover Short Interest1
Basic Shares Quantity51,184,407
Short % of Basic Shares0.1%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/29/20250.7%-0.7%-9.0%
6/11/2025-27.7%-31.9%-22.5%
3/14/20251.1%1.6%-9.8%
11/7/20242.6%-2.1%0.5%
6/14/20243.5%-0.7%5.6%
3/14/20240.6%-0.6%5.8%
10/30/20233.5%4.6%2.3%
6/13/2023-2.3%-3.6%-4.5%
...
SUMMARY STATS   
# Positive1079
# Negative8119
Median Positive3.1%3.3%5.8%
Median Negative-5.3%-2.1%-17.2%
Max Positive18.2%22.9%35.0%
Max Negative-27.7%-34.1%-79.1%

SEC Filings

Expand for More
Report DateFiling DateFiling
103120251212202510-Q 10/31/2025
73120251029202510-K 7/31/2025
4302025611202510-Q 4/30/2025
1312025314202510-Q 1/31/2025
103120241211202410-Q 10/31/2024
73120241107202410-K 7/31/2024
4302024614202410-Q 4/30/2024
1312024314202410-Q 1/31/2024
103120231214202310-Q 10/31/2023
73120231030202310-K 7/31/2023
4302023613202310-Q 4/30/2023
1312023314202310-Q 1/31/2023
103120221213202210-Q 10/31/2022
73120221031202210-K 7/31/2022
4302022614202210-Q 4/30/2022
1312022317202210-Q 1/31/2022